Retatrutide
A novel triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously.
Research Use Only. This product is intended for laboratory research purposes only and is not for human consumption. Not for sale to minors.
Product Description
Retatrutide is a novel triple agonist that simultaneously targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. Research has investigated whether this triple mechanism produces superior metabolic effects compared to dual or single agonists.
Research Information
Early-phase research on retatrutide has demonstrated substantial effects on body weight and metabolic parameters. Studies have explored the additive contributions of glucagon receptor agonism to the already established benefits of GIP/GLP-1 dual agonism. Research has also examined effects on lipid metabolism, liver fat, and cardiovascular risk markers.
Dosage Guidance
Research protocols use dose-escalation strategies with subcutaneous administration. All dosing information is for research reference only.